PCSK9 and prostate cancer: Genetically proxied inhibition of PCSK9 was strongly associated with a lower risk of developing prostate cancer (IVW MR odds ratio (OR) = 0.85, 95% confidence interval (95% CI) = 0.76 to 0.96, P = 0.009, per standard deviation (SD) reduction in LDL-c).